SuperworthAnaptysbio ANAB
- Market cap
- $1.5B
- PE
- 10.7×
- 5y median 100.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- Q4 FY26 missing
- EV/EBIT
- n/m
- a quarter missing
- Revenue, 12 months
- n/m
- Q4 FY26 missing
- Net margin
- n/m
- Q4 FY26 missing
- Free cash flow yield
- n/m
- Q4 FY26 missing
Anaptysbio trades at 10.7× trailing earnings.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.3M+157% | $9M+32% | $7.2M+423% | $11M+217% | $30M+805% | $43.1M+379% | $27.8M+287% | $22.3M+103% | $76.3M+154% | $108.2M+151% | $25.6M−8% | n/a | |
| R&D | $30.9M+40% | $33.5M+43% | $37M+6% | $42M+28% | $42.2M+37% | $42.6M+27% | $41.2M+11% | $37.8M−10% | $31.4M−26% | $25.6M−40% | $34M−18% | n/a |
| SG&A | $10.2M+15% | $10.3M+9% | $12.3M+14% | $9.3M−13% | $10.6M+4% | $10.2M−1% | $14.1M+15% | $10.6M+14% | $10.2M−3% | $15.8M+55% | $26.2M+85% | n/a |
| −$37.7M+27% | −$42.1M+62% | −$42.2M−5% | −$40.3M+0% | −$22.8M−40% | −$9.7M−77% | −$27.5M−35% | −$26.2M−35% | $34.7M | $66.9M | −$34.6M+26% | n/a | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$37.3M | −$42.2M | −$43.9M | −$46.7M+17% | −$32.9M−12% | −$21.8M−48% | −$39.3M−11% | −$38.6M−17% | $15.1M | $49.7M | −$52.8M+35% | n/a |
| $0 | −$4K | $0 | $9K | $0 | −$6K+50% | $44K | $39K+333% | $0 | $81K | $40K−9% | n/a | |
| Net income | −$37.3M+11% | −$42.2M+60% | −$43.9M−1% | −$46.7M+17% | −$32.9M−12% | −$21.8M−48% | −$39.3M−11% | −$38.6M−17% | $15.1M | $49.6M | −$52.9M+35% | $183.9M |
| −$0.94+20% | −$1.06+71% | −$1.09+4% | −$1.14+14% | −$0.76−19% | −$0.48−55% | −$0.85−22% | −$0.89−22% | $0.35 | $1.19 | −$1.84+116% | $4.87 | |
| 39.8M−6% | 39.9M−7% | 40.2M−4% | 41M+3% | 43.3M+9% | 45.7M+15% | 46M+14% | 43.2M+5% | 43.5M+0% | 41.7M−9% | 28.7M−38% | 37.8M−13% |
EPS, diluted: 11 periods, Q2 FY16 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY17 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY26: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Anaptysbio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $1.5B | 14.1× | 17.2× | 1.9× | +14% | 11.1% |
More on Anaptysbio
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .